^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + EGFR G724S + EGFR T790M
    Cancer:Lung Adenocarcinoma
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    IASLC-WCLC 2023
    Title:

    Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation

    Published date:
    08/08/2023
    Excerpt:
    The patient began afatinib 30 mg daily while continuing osimertinib 80 mg daily on March 20, 2022. After 2 month, the patient’s respiratory symptoms were significantly relieved, and after 5 months, follow-up CT showed that the patient’s pulmonary mass in the right lower lobe were significantly reduced...The combination therapy of afatinib and osimertinib could be a new therapeutic option for patients with lung adenocarcinoma harboring EGFRG724S/T790M/19Del mutation.